Cargando…
Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine/tenofovir disoproxil fumarate for medication of treatment-naïve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96
BACKGROUND: Ainuovirine (ANV) is a new non-nucleoside reverse transcriptase inhibitor (NNRTI), which was initially synthesized in Korea and later further developed in both Korea and China. METHODS: A randomized, double-blind, double-dummy, positive parallel group, non-inferiority, phase 3 trial was...
Autores principales: | Su, Bin, Gao, Guiju, Wang, Min, Lu, Yanqiu, Li, Linghua, Chen, Chen, Chen, Yuanyuan, Song, Chuan, Yu, Fengting, Li, Ying, Liu, Yixin, Luo, Yang, He, Haolan, Cheng, Cong, Xu, Lixia, Zhang, Tong, Sun, Lijun, Liu, An, Xia, Wei, Qin, Yuanyuan, Zhao, Qingxia, Wei, Hongxia, Cai, Weiping, Chen, Yaokai, Zhang, Fujie, Wu, Hao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398592/ https://www.ncbi.nlm.nih.gov/pubmed/37547039 http://dx.doi.org/10.1016/j.lanwpc.2023.100769 |
Ejemplares similares
-
Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
por: Deng, Lisi, et al.
Publicado: (2022) -
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial
por: Orkin, Chloe, et al.
Publicado: (2019) -
Simultaneous Spectrophotometric Estimation of Tenofovir Disoproxil Fumarate and Lamivudine in Three Component Tablet Formulation Containing Efavirenz
por: Sharma, R., et al.
Publicado: (2010) -
96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients
por: Liu, Zhihong, et al.
Publicado: (2023) -
Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks
por: Tebas, Pablo, et al.
Publicado: (2015)